EXPERIENCE IN TREATMENT OF A PATIENT WITH ISONIAZIDE-RESISTANT PULMONARY TUBERCULOSIS

Isoniazid-resistant tuberculosis (HR-TB) is characterized by resistance to isoniazid and sensitivity to rifampicin. This form can be viewed as a potential precursor to multidrug-resistant tuberculosis (MDR-TB). According to the WHO, the prevalence of HRTB is 5.0–11.0% on average. Therefore, it is of course important to control the spread of primary isoniazid resistance and prevent the amplification of resistance. WHO currently recommends treatment with rifampicin (R), ethambutol (E), pyrazinamide (Z) and levofloxacin (Lfx) for 6 months for patients with confirmed HR-TB. Since the end of 2020, this regime has begun to be implemented in the Republic of Kazakhstan. In clinical phthisiology in the country, there is not yet sufficient experience in the treatment of HR-TB. We observed the successful treatment of a patient with isoniazid-resistant TB using the 6REZLfx regimen, and the authors felt it necessary to share their experience with a wide range of TB - doctors

1. Доклад о глобальной борьбе с ТБ - Женева: ВОЗ,2020.

2. СВОДНОЕ РУКОВОДСТВО ВОЗ ПО ЛЕЧЕНИЮ ЛЕКАРСТВЕННО-УСТОЙЧИВОГО ТУБЕРКУЛЕЗА. – Женева: ВОЗ. Европейское бюро, 2016.

3. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: WHО; 2019 (WHO/CDS/TB/2019.33).

4. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J TubercLung Dis. 2009; (13): 1320–30.

5. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., Murray M.B. Tuberculosis drug resistance mutation data base. PLoSMed. 2009; 6 (2): e2.

6. Gegia M., Winters N., Benedetti A., van Soolingen D., Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. LancetInfectDis. 2017; 17 (2): 223–34.

7. World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. - Geneva: WНО; 2018 (WHO/CDS/TB/2018.7).

8. Андреевская С.Н., Смирнова Т.Г., Ларионова Е.Е., Андриевская И.Ю, Черноусова Л.Н., Эргешов А. Изониазид-резистентные Mycobacterium tuberculosis: частота выявления, спектры резистентности и генетические детерминанты устойчивости //ВЕСТНИК РГМУ. -2020. - №1. - С.22-28.

9. Приказ Министра здравоохранения Республики Казахстан от 30 ноября 2020 года №214 ҚР ДСМ-214/2020 «Об утверждении правил проведения мероприятий по профилактике туберкулеза».